Mizuho Securities Thinks ContraFect’s Stock is Going to Recover


In a report released yesterday, Vamil Divan from Mizuho Securities reiterated a Buy rating on ContraFect (CFRX), with a price target of $10.00. The company’s shares closed last Friday at $3.83, close to its 52-week low of $3.44.

According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.1% and a 50.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ContraFect with a $12.00 average price target, representing a 235.2% upside. In a report issued on May 3, Maxim Group also assigned a Buy rating to the stock with a $14.00 price target.

See today’s analyst top recommended stocks >>

ContraFect’s market cap is currently $150.6M and has a P/E ratio of -2.20. The company has a Price to Book ratio of 11.94.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ContraFect Corp. is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts